Be Patient, and Wait for a Return of Favor<br />By Rev Shark<br />RealMoney.com Contributor<br />8/4/2009 8:48 AM EDT <br /><br />When all the world is young, lad,<br />And all the trees are green;<br />And every goose a swan, lad,<br />And every lass a queen;<br />Then hey for boot and horse, lad,<br />And round the world away;<br />Young blood must have its course, lad,<br />And every dog his day. <br />-- "The Water Babies" by C. Kingsley<br /><br />As the market has gone straight up without a pause over the last couple of weeks, I have written numerous times about how this isn't necessarily such an easy market for many market players. When you see the celebration in the media and constantly read about the wonderfulness of it all, it is quite easy to feel like you might be missing out. And in fact, most active market players are missing out to some degree. <br /><br />The folks who benefit the most in a market that goes straight up are those who stay fully invested and use a buy-and-hold approach. If you simply stayed fully long for the last couple of weeks, you have had the superior investment strategy for this market. <br /><br />A more active approach to the market over the last few weeks -- where you locked in gains as stocks became extended and looked to buy pullbacks as they occurred -- would have left you underperforming. Your sales would have been too early, as things just kept on running, and your new buys would be negligible because pullbacks just weren't occurring. <br /><br />Of course, the reverse would have been the case as the market fell apart last year and earlier this year. The fully invested, buy-and-hold approach would have cost you dearly, while the more active approach would have likely yielded far superior results. <br /><br />There isn't anything particularly profound about that observation, but it is important because people tend to forget how styles fall in and out of favor. If you are active in the markets, it is inevitable that you will go through periods of frustration and underperformance. It is the nature of the beast, and there isn't much you can do about it. You might try to reinvent your investing style as the market evolves, but that is tremendously difficult. Not only does your timing have to be quite good, but you also have to adjust to a new approach that may be uncomfortable and unfamiliar. <br /><br />If you have been feeling frustrated at being underinvested as this market runs away, I can assure you that you will have your day again. The important thing is that you not let emotions push you to do something rash. You just need to embrace the fact that the market is full of cycles and that eventually every dog will have his day. <br /><br />We have a slight pause in the action this morning. The news wires are quite slow and a little profit-taking is kicking in. The market has been way too strong to suddenly and completely fall apart, but the likelihood of hitting an air pocket at this lofty altitude is quite high. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: TAST +14.3%, CRAY +10.2%, CTSH +6.7%, WMS +6.1% (also upgraded to Overweight from Neutral at JP Morgan), SNTS +5.7%, WLK +5.2% (light volume), SYKE +5.1% (light volume), CVS +4.4%, EXBD +4.1%, CAM +3.2%... M&A news: PAS +7.1% and PBG +6.4% (Bloomberg reports that PEP is said to be near a takeover agreement with bottlers)... Other news: MELA +12.7% (FDA Accepts MELA's MelaFind Pre-Market Approval application for review), CNO +8.7% (continued momentum), GLBL +4.7% (into exclusive agreement with Fluor Offshore Solutions to jointly pursue Middle East projects), ONTY +4.4% (continued momentum from yesterday's 30%+jump), HURN +2.3% (modestly rebounding from yesterday's 30 point drop), CIG +1.7% (Cramer makes positive comments on MadMoney), CEPH +1.5% (says Journal of Clinical Oncology Publishes TREANDA study demonstrating 'significant improvement' in overall response and progression-free survival in chronic lymphocytic leukemia)... Analyst comments: SVVS +3.6% (upgraded to Overweight at Morgan Stanley), HGSI +2.8 (upgraded to Buy at ThinkEquity). <br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: HLF -18.4%, STEC -9.9% (also announces secondary offering of 7.5 mln shares of common stock), IPHS -9.0%, UBS -8.1%, ADM -7.9%, G -7.1% (light volume), HOLX -5.6%, ATML -5.6%, EXPD -5.2% (light volume), PPL -5.0% (also downgraded to Hold from Buy at Soleil), ZBRA -4.9%, CTX -4.6%, TIE -4.4%, EMS -4.2% (also intends to commence a 7 mln share common stock offering), VMC -3.8%, ARNA -3.6% (also filed for a 28 mln share common stock offering by selling shareholders), TXRH -3.1%, PHM -2.6%, SPG -1.8%, TM -1.1%... Select financial names showing weakness: IRE -10.8%, ING -3.2%, AXA -2.8%, HBC -2.8% (hires CICC, Citic on $3 bln - 5 bln a-share IPO, according to sources - DJ), LYG -2.4%, RBS -2.4%, ABB -2.1%, HIG -2.1%, FITB -1.9%, BAC -1.1%, MS -1.1%, JPM -1.0%... Select oil/gas names trading lower: PTR -2.9%, CEO -2.3%, E -2.3%, BP -1.3%, RIG -1.3%, OXY -1.2%, SLB -1.2%... Select metals/mining names showing weakness: MT -3.6%, RTP -3.5%, BHP -2.6% (BHP names ex-Ford CEO as Chairman - WSJ), BBL -2.3%, ABX -0.8% (downgraded to Sector Perform from Outperform at CIBC Wrld Mkts)... Other news: ARIA -8.0% (announces public offering of 17,000,000 shares), SFY -7.1% (announces offering of 5,000,000 shares of common stock), NABI -6.8% (still checking), SIRO -5.4% (proposes public secondary offering of 7,500,000 shares), ENOC -5.0% (announces 3.75 mln common share offering), CENX -3.7% (still checking), AKS -2.1% (announces September 2009 surcharges $170 per ton for electrical and stainless steels)... Analyst comments: LAMR -6.3% (cut to Sell from Neutral at Goldman- Reuters), SVNT -4.7% (downgraded to Underperform at Jefferies), AIXG -4.5% (downgraded to Neutral at Credit Suisse), CBS -3.5% (cut to Sell from Hold at Natixis), FTE -2.7% (downgraded to Neutral at BofA/Merrill).